Third Rock Bets $40 Million On Blueprint Medicines

Apr 11, 2011, 11:25 AM by Michael Croft

Boston Globe | Boston venture capital firm Third Rock Ventures is pumping $40 million into Blueprint Medicines, a new company founded by the discoverers of Gleevec that will develop targeted therapies for cancer.

April 11, 2011 | Boston venture capital firm Third Rock Ventures is pumping $40 million into Blueprint Medicines, a new company that will develop targeted therapies for cancer. Blueprint is co-founded by Brian Druker and Nicholas Lydon, the oncologists who discovered the leukemia drug Gleevec, sold by Novartis. Boston Globe